do glp-1 agonists have cardiovascular benefit Receptor for the Reduction of Atherosclerotic Risk in Patients With Type 2 Diabetes Benefits and drawbacks of GLP-1

Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism

Pills are also easier to manufacture than injectable pens, which could help avoid the frustrating supply problems that slowed earlier GLP-1 launches

While North America held the largest market share for GLP-1 RA medications in 2024, with Europe following, Asia-Pacific is expected to exhibit the fastest growth market due to rising diabetes and obesity rates 13

Risks: Increased heart rate, potential worsening of heart failure with reduced ejection fraction, and rare complications like hypoglycemia or retinopathy

55 Moreover, many novel monotherapies target different mechanistic approaches, so combination therapy is an attractive approach that is currently under investigation

Pennington Biomedical Research Center 6400 Perkins Road Baton Rouge, LA 70808